Genomics ( IF 4.4 ) Pub Date : 2021-07-21 , DOI: 10.1016/j.ygeno.2021.07.010 Lei Zhang 1 , Dapeng Li 1 , Fenqi Du 2 , Hao Huang 1 , Chao Yuan 2 , Jinming Fu 1 , Simin Sun 1 , Tian Tian 1 , Xinyan Liu 1 , Hongru Sun 1 , Lin Zhu 1 , Jing Xu 1 , Yanlong Liu 2 , Binbin Cui 2 , Yashuang Zhao 1
We aim to identify a panel of differentially methylated regions (DMRs) for predicting survival outcomes for patients with CRC from the TCGA (n = 393). Four DMRs (MUC12, TBX20, CHN2, and B3GNT7) were selected as candidate prognostic markers for CRC. The prediction potential of selected DMRs was validated by the targeted bisulfite sequencing method in an independent cohort with 251 Chinese CRC patients. DMR methylation scores (DMSs) were constructed to evaluate the prognosis of CRC. Results of the validation cohort confirmed that higher DMSs were associated with poor overall survival (OS) of CRC, with hazard ratio (HR) value ranged from 1.445 to 2.698 in multivariable Cox models. Patients in the high prognostic index (high-PI) group showed a markedly unfavorable prognosis compared to the low-PI group in both TCGA discovery cohort (HR = 3.508, 95%CI: 2.196–5.604, P < 0.001) and independent validation cohort (HR = 1.912, 95%CI: 1.258–2.907, P = 0.002).